搜尋結果
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek[2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ...
- 2008; 15 years ago
- Mainz, Germany
- 4,530 (2022)
- Biotechnology
Medical uses. The Pfizer–BioNTech COVID-19 vaccine is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus, by eliciting an immune response to the S antigen. [1] [2] [30] [39] The vaccine is used to reduce morbidity and mortality from COVID-19.
- Comirnaty
- mRNA
其他人也問了
Who is the CEO of biontech?
What does biontech stand for?
Where is biontech based?
Why did the European Investment Bank sign a deal with biontech?
Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, , .
Özlem Türeci ( Turkish pronunciation: [ˈœzlem ˈtyredʒi]; born 6 March 1967) is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA -based vaccine approved for use against COVID-19. [2]
- 1
- 1992–present
- Germany
RNA vaccines are the first COVID‑19 vaccines to be authorized in the United Kingdom, the United States, and the European Union. [56] [57] Authorized vaccines of this type are the Pfizer–BioNTech [58] [59] [60] and Moderna vaccines. [61] [62] The CVnCoV RNA vaccine from CureVac failed in clinical trials.
Vaccination center in Samsun. Turkey currently uses 4 different COVID-19 vaccines. [5] [6] BioNTech vaccination room in Turkey. Vaccination statistics. New vaccination per day 7-day moving average. First dose Second dose. Gallery. Vaccines used in Turkey. Sinovac. BioNTech. Sputnik V. See also.
A regimen of two doses of the Oxford–AstraZeneca vaccine followed by a booster dose of the Pfizer–BioNTech or the Moderna vaccine is initially about 60% effective against symptomatic disease caused by Omicron, then after 10 weeks the effectiveness drops to
